Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|April 1, 2000
Supplements and Featured Publications
- Asthma Management Alternatives for the New Millennium
- Volume 6
- Issue 7 Suppl
The 1997 Asthma Guidelines and an Asthma Clinical Update
Author(s)Stuart Stoloff, MD
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Discussion: Implementing the 1997 Asthma Guidelinesover 26 years ago
Overview of HEDIS 2000 Asthma Measurementover 26 years ago
Discussion: Using the HEDIS Asthma Measurementover 26 years ago
Discussion: The Impact of Allergens on Asthma Severity and Treatmentover 26 years ago
Adjunctive Therapy: Treatment Optionsover 26 years ago
Discussion: Treatment Options for Asthmaover 26 years ago
Pharmacoeconomic Impact of Inhaled CorticosteroidsAdvertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
5